Abliva AB (publ) (OTCMKTS:NEVPF) & Applied Molecular Transport (NASDAQ:AMTI) Critical Comparison
Abliva AB (publ) (OTCMKTS:NEVPF – Get Rating) and Applied Molecular Transport (NASDAQ:AMTI – Get Rating) are both small cap medical companies, but which is the better company? We will compare the two companies based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.
This is a summary of current recommendations and price targets for Abliva AB (publ) and Applied Molecular Transport, as reported by MarketBeat.com.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
|Abliva AB (publisher)||0||0||0||0||N / A|
|Applied Molecular Transport||0||0||2||0||3.00|
Applied Molecular Transport has a consensus target price of $75.00, suggesting a potential upside of 1,738.24%. Given Applied Molecular Transport’s possible higher upside, analysts clearly believe that Applied Molecular Transport is more favorable than Abliva AB (publ).
Insider and Institutional Ownership
71.3% of Applied Molecular Transport shares are held by institutional investors. 25.4% of the shares of Applied Molecular Transport are held by insiders. Strong institutional ownership indicates that endowments, hedge funds, and large fund managers believe a company will outperform the market over the long term.
Valuation and benefits
This table compares the gross revenue, earnings per share (EPS) and valuation of Abliva AB (publ) and Applied Molecular Transport.
|Gross revenue||Price/sales ratio||Net revenue||Earnings per share||Price/earnings ratio|
|Abliva AB (publisher)||$20,000.00||674.18||-$6.54 million||N / A||N / A|
|Applied Molecular Transport||N / A||N / A||-$100.29 million||($3.18)||-1.28|
Abliva AB (publ) has higher revenues and profits than Applied Molecular Transport.
This table compares the net margins, return on equity and return on assets of Abliva AB (publ) and Applied Molecular Transport.
|Net margins||Return on equity||return on assets|
|Abliva AB (publisher)||N / A||-81.15%||-71.29%|
|Applied Molecular Transport||N / A||-71.26%||-59.20%|
Applied Molecular Transport beats Abliva AB (publ) on 6 of the 8 factors compared between the two stocks.
Company profile Abliva AB (publ) (Get an evaluation)
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 which is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in preparation for clinical trials for the treatment of primary mitochondrial diseases with complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children’s Hospital of Philadelphia, Patheon and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden .
Applied Molecular Transport Company Profile (Get an evaluation)
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic and other diseases. The Company’s lead product candidate is AMT-101, an oral selective gastrointestinal (GI) fusion of rhIL-10 that is in a Phase II clinical trial for the treatment of ulcerative colitis and associated inflammatory indications. It is developing AMT-126, an oral GI-selective interleukin-22 fusion, which is in a Phase I clinical trial for diseases related to defects in the barrier function of the intestinal epithelium. The Company, through its technology platform, designs and develops various oral biological therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments and ribonucleic acid therapies. Applied Molecular Transport Inc. was founded in 2010 and is based in South San Francisco, CA.
Receive news and reviews for Abliva AB (publ) daily – Enter your email address below to receive a concise daily summary of breaking news and analyst notes for Abliva AB (publ) and related companies with MarketBeat.com’s free daily email newsletter.